We are introducing a group of antibodies against cytoskeletal antigens that can be used as markers in neurobiology.
European Commission extended deadlines for the implementation of the new IVDR (Regulation No. 2017/746) in order to avoid disruption of the supply of in vitro medical devices.
Today we introduce four mouse monoclonal antibody clones, that have been added to our portfolio: Anti-human TROP2 (clone TrMab-6), anti-human TCR gamma/delta (clone 11F2), anti-human CD272 (MIH26), anti-human granzyme A (CB9).
Accordingly to most recent studies, SCIMP appears to be a key, well defined component in initiation TLR-mediated pro-inflammatory responses in macrophages.
Trop-2 is thought to be associated with the epithelial phenotype of cancer cells and many studies have reported that epithelial markers positively correlate with its expression, whereas mesenchymal markers typically exert negative correlation.
Cytokeratins are a subfamily of intermediate filaments and are characterized by remarkable biochemical diversity. Among other applications, they also can be used as markers for detection and characterization of circulating tumor cells.
Within the programmed cell death pathway, the interaction between PD-1 and PD-L1 and L2 particularly affects T-lymphocytes, in which they cause a phenomenon called functional exhausting, by attenuating TCR-mediated T-cell proliferation by negative costimulation control of activation of T-lymphocytes during the presentation of antigens by dendritic cells.
We present here a brief comparison of TB3, UCHT1, and MEM-57 anti-CD3 flow cytometric antibodies, that have been submitted to HLDA workshops in past.
The monoclonal antibody JOVI.1 recognizes the TRBC1+ region and enables fast and reliable assessment of clonal restriction of TCR C genes by flow cytometry.